Neil E. Kay, MD, professor of medicine at the Mayo Clinic, addresses the “Big 4” in salvage therapies for patients with relapsed/refractory chronic lymphocytic leukemia, including a newer therapy coming down the pipeline now.
Neil E. Kay, MD, professor of medicine at the Mayo Clinic, addresses the “Big 4” in salvage therapies for patients with relapsed/refractory chronic lymphocytic leukemia (CLL), including a newer therapy coming down the pipeline now.
Based on findings from clinical trials, Kay says the 4 major salvage therapies right now include ibrutinib (Imbruvica), venetoclax (Venclexta), idelalisib(Zydelig)/rituximab (Rituxan), and allogeneic bone marrow transplant. While it remains unclear in which order to administer these treatments, a wise decision can be made based off a patient’s age, comorbidities, and treatment goals.
Novel Approaches Focus on Limiting Toxicity in Older Patients With ALL
April 22nd 2024The major challenges for clinicians treating older patients with acute lymphoblastic leukemia surround the emergence of resistance to existing therapies and the toxicities associated with current chemotherapies.
Read More